Julie Kim is set to replace Christophe Weber as the new chief executive officer of Takeda Pharmaceutical Co., becoming the first woman to lead the more than 240-year-old Japanese drugmaker.

Takeda has named Julie Kim as its next CEO. She will replace Christophe Weber who plans to step down in June of 2026 after leading Japan’s largest drugmaker for 11 years. The company called the ...

January 30, 2025--(BUSINESS WIRE)--Takeda (TOKYO:4502/NYSE:TAK) announced today that its Board of Directors made the decision unanimously to appoint Julie Kim, currently president of Takeda’s U ...

The current approval of Takeda’s Takhzyro pre-filled pen is an addition to the existing 150 mg and 300 mg pre-filled syringes ...

On Thursday, Takeda Pharmaceutical Co. (NYSE:TAK) announced that its board of directors had selected Julie Kim, president of Takeda’s U.S. business unit, as Weber’s successor. The life ...

Takeda Pharmaceutical 45021.37%increase; green up pointing triangle named Julie Kim, who heads its U.S. business, as its new chief executive starting in 2026, elevating her to the small but ...

Takeda has announced the appointment of Julie Kim as successor to Christophe Weber, its current president, CEO and representative director, effective from June 2026. The decision was unanimously ...

He will be replaced by Julie Kim, currently president of Takeda’s U.S. business unit, making her one of the few female chief executives in the pharma industry or of a major Japanese company.

CEO Christophe Weber to retire from Takeda in June 2026 after 12 years Julie Kim, president of the U.S. Business Unit, named to succeed Weber after multi-year succession process “The Board of ...

The issuer is solely responsible for the content of this announcement. “The Board of Directors has unanimously chosen Julie Kim to lead Takeda into the next chapter, building on the company’s success ...